Crossmark

Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis

Crossref DOI link: https://doi.org/10.1007/s40259-019-00376-z

Published Online: 2019-08-24

Published Print: 2019-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Soohyun https://orcid.org/0000-0002-4798-2545
Lee, Heeyoung

Kim, EunYoung https://orcid.org/0000-0003-3525-8805
Funding

Funding for this research was provided by:

Chung-Ang University

Ministry of Education (NRF-2018R1D1A1B07046564)
License Information

Text and Data Mining valid from 2019-08-24

Version of Record valid from 2019-08-24
More Information

Article History

First Online: 24 August 2019

Compliance with Ethical Standards

:

: This research is supported by the 2019 Chung-Ang University Research Scholarship Grants (Soohyun Lee) and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B07046564).

: Soohyun Lee, Heeyoung Lee, and Eunyoung Kim declare that they have no competing interests related to this study.

: Ethical approval was not applicable for this systematic review and meta-analysis.

: All the materials used in this systematic review and meta-analysis have been fully referenced.

Document is current

Any future updates will be listed below